1 | assay and reagent services | | | | | | | 2 | 0.40% |
2 | biology medicinal chemistry highthroughput | | | | | | | 2 | 0.40% |
3 | large molecules assay and | | | | | | | 2 | 0.40% |
4 | molecules assay and reagent | | | | | | | 2 | 0.40% |
5 | and reagent services admepk | | | | | | | 2 | 0.40% |
6 | reagent services admepk in | | | | | | | 2 | 0.40% |
7 | services admepk in vivo | | | | | | | 2 | 0.40% |
8 | integrated drug discovery services | | | | | | | 2 | 0.40% |
9 | structural biology medicinal chemistry | | | | | | | 2 | 0.40% |
10 | medicinal chemistry highthroughput and | | | | | | | 2 | 0.40% |
11 | conjugates therapeutic areas inflammation | | | | | | | 1 | 0.20% |
12 | services offered integrated drug | | | | | | | 1 | 0.20% |
13 | derived primary cells ipscs | | | | | | | 1 | 0.20% |
14 | primary cells ipscs therapeutic | | | | | | | 1 | 0.20% |
15 | offered integrated drug discovery | | | | | | | 1 | 0.20% |
16 | cells ipscs therapeutic class | | | | | | | 1 | 0.20% |
17 | ipscs therapeutic class smallmolecules | | | | | | | 1 | 0.20% |
18 | therapeutic class smallmolecules protacs | | | | | | | 1 | 0.20% |
19 | infection services offered integrated | | | | | | | 1 | 0.20% |
20 | oncology immunooncology metabolic diseases | | | | | | | 1 | 0.20% |
21 | antibody cart antibodydrug conjugates | | | | | | | 1 | 0.20% |
22 | disorder infection services offered | | | | | | | 1 | 0.20% |
23 | cart antibodydrug conjugates therapeutic | | | | | | | 1 | 0.20% |
24 | antibodydrug conjugates therapeutic areas | | | | | | | 1 | 0.20% |
25 | discovery services small and | | | | | | | 1 | 0.20% |
26 | metabolic diseases fibrosis autoimmune | | | | | | | 1 | 0.20% |
27 | immunooncology metabolic diseases fibrosis | | | | | | | 1 | 0.20% |
28 | drug discovery services small | | | | | | | 1 | 0.20% |
29 | email protected 918527201536 home about | | | | | | | 1 | 0.20% |
30 | small and large molecules | | | | | | | 1 | 0.20% |
31 | services flow discussion with | | | | | | | 1 | 0.20% |
32 | submission with goals timelines | | | | | | | 1 | 0.20% |
33 | proposal submission with goals | | | | | | | 1 | 0.20% |
34 | team proposal submission with | | | | | | | 1 | 0.20% |
35 | scientific team proposal submission | | | | | | | 1 | 0.20% |
36 | with clients recommendations by | | | | | | | 1 | 0.20% |
37 | discussion with clients recommendations | | | | | | | 1 | 0.20% |
38 | flow discussion with clients | | | | | | | 1 | 0.20% |
39 | screening services flow discussion | | | | | | | 1 | 0.20% |
40 | and large molecules assay | | | | | | | 1 | 0.20% |